# Contact PT-141 Clinic: Editorial Correspondence

> Contact PT-141 Clinic, an independent editorial project summarizing the PT-141 (bremelanotide) research and label record. Editorial correspondence only; no medical advice and no products.

Corrections, source suggestions, and editorial correspondence about the bremelanotide record. We do not provide medical advice and we do not sell anything.

## Editorial correspondence

Use the form below for editorial matters — a correction, a study we have missed, a citation that needs fixing, or a question about how we have read a source. We read every message and we update the record when the literature warrants it. We are most grateful for pointers to peer-reviewed work that sharpens or corrects what is here.

What we cannot answer is anything clinical. We are not a clinic and we do not have clinicians. We cannot advise on whether PT-141 (bremelanotide) is appropriate for any person, cannot recommend a dose, and cannot interpret anyone's medical situation. Those questions belong with a qualified healthcare professional who knows the individual.

## What not to send

Please do not send requests to buy, source, or price the compound — we do not sell it, link to sellers, or maintain vendor information, and we cannot help with procurement of any kind. Please do not send personal health details seeking advice; we are not able to act on them and they belong with your clinician, not an editorial inbox. Messages of those two kinds will not receive a substantive reply, because answering them is outside what this project does and what it is able to do responsibly.

---

An after-dark poster reading of the bremelanotide record — the one approved use staged apart from the off-label male research, the modest endpoints set beside the numbers that qualify them, the nausea-led tolerability cost read in full, and the field reports pinned plainly to one side as unverified; no clinic behind the wall, and nothing here dosed, dispensed, or sold.